Loading...
•
Dec 31, 2025
Belite Bio Q4 2025 Earnings Report
Belite Bio reported its preliminary unaudited fourth quarter 2025 financial results with increased operating expenses and a wider net loss following expanded clinical and corporate activities.
Key Takeaways
Belite Bio reported a GAAP net loss of 25324000 for Q4 2025, driven by higher R&D and G&A expenses associated with clinical trials and share-based compensation, while strengthening its balance sheet with significant cash and investments following a public offering.
GAAP net loss was 25324000 compared to 10100000 in Q4 2024.
R&D expenses increased to 14624000 from 7254000 year-over-year.
G&A expenses rose to 13453000 from 4203000 year-over-year.
Cash and investments totaled 772600000 at December 31, 2025.
Forward Guidance
The Company remains on track to submit an NDA for tinlarebant to the FDA in Q2 2026 and continue advancing its Phase 2/3 and Phase 3 trials, supported by strengthened capital resources.
Positive Outlook
- On track to submit NDA in Q2 2026.
- Completed enrollment in DRAGON II trial.
- PHOENIX Phase 3 trial fully enrolled.
- Completed 402000000 public offering to support commercialization.
- Strong liquidity position with substantial cash and investments.
Challenges Ahead
- Increased R&D expenses due to clinical trial activities.
- Higher G&A expenses driven by share-based compensation.
- Net loss widened year-over-year.
- No product revenue generated.
- Continued dependence on successful regulatory approval.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...